Ruxolitinib Cream Hit 79% Response Rate in HS Phase 2 Trial
A phase 2 trial found ruxolitinib 1.5% cream (Opzelura) produced a 79% response rate in mild to moderate hidradenitis suppurativa. Phase 3 trials are now underway.
A phase 2 trial found ruxolitinib 1.5% cream (Opzelura) produced a 79% response rate in mild to moderate hidradenitis suppurativa. Phase 3 trials are now underway.
We use cookies for analytics and site preferences. Choose what to allow. Cookie policy